Artículos relacionados
Área salud
Real-World Clinical, Psychosocial and Financial Burden of Atopic Dermatitis: Results from the Spanish Cohort of the MEASURE-AD Trial
enero 15, 2025
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 116. Núm. 1. (enero 2025)
Background Atopic dermatitis (AD) is one of the most prevalent skin diseases, but there are numerous knowledge gaps surrounding the impact this disease has on quality of life (QoL), mental health, and out-of-pocket expenses involved […]
Área salud
FR-Espaciamiento de la dosis de dupilumab en dermatitis atópica: ¿optimización o fracaso terapéutico?
noviembre 5, 2024
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 115. Núm. 8. (septiembre 2024)
Área salud
[Translated article] Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis
diciembre 27, 2022
Área salud, Actas Dermo-Sifiliográficas, Elsevier España, Medicina, Vol. 113. Núm. 7. (Julio - Agosto 2022)
Interleukin 31 (IL-31) is a neurocytokine that stimulates sensory neurons involved in pruritus. It contributes to skin barrier inflammation, dysfunction, and remodeling. As the immune and nervous systems are interrelated, IL-31 has a key role […]
